Two Cases of Primary Ciliary Dyskinesia with Different Responses to Macrolide Treatment

Takashi Kido¹, Kazuhiro Yatera¹, Kei Yamasaki¹, Shuya Nagata¹, Yasuo Choujin¹, Chiyo Yamaga¹, Kanako Hara¹, Hiroshi Ishimoto¹, Masanori Hisaoka² and Hiroshi Mukae¹

Abstract

We herein report two cases of primary ciliary dyskinesia (PCD) with different responses to macrolides. Case 1: a 17-year-old Japanese man with Pseudomonas aeruginosa infection and combined defect of both inner and outer dynein arms in the cilia was unsuccessfully treated with long-term macrolides (clarithromycin, erythromycin, and azithromycin). Case 2: a 70-year-old Japanese man with deficiency of only the inner dynein arm was successfully treated with clarithromycin. Though the reasons for the different responses to macrolides are unclear, differences of ultrastructural abnormalities of the cilia might be one of the predictive factors in PCD just as in Pseudomonas aeruginosa infection.

Key words: azithromycin, clarithromycin, dynein arm, immotile cilia, macrolide, primary ciliary dyskinesia

(DOI: 10.2169/internalmedicine.51.6617)

Introduction

Primary ciliary dyskinesia (PCD), a rare disease estimated to affect 1 in 15,000 to 20,000 individuals, is accompanied by ciliary dysfunction (1, 2). The ciliary beat frequency (CBF) is closely associated with specific ultrastructural abnormalities of the cilia in patients with PCD. With regard to the ciliary motility in patients with PCD, Chilvers et al. reported that inner dynein arm (IDA) defect is associated with relatively mild dysfunction, while the presence of a combined defect of both IDA and the outer dynein arm (ODA) is associated with severe dysfunction (3). The ciliary beat is an important primary innate defense mechanism, and ciliary dysfunction leads to upper and lower respiratory diseases such as chronic bronchitis, bronchiectasis, chronic sinusitis and chronic otitis media from infancy in patients with PCD. There are no standardized effective treatment strategies for PCD, although the lung involvement of PCD can develop into severe or fatal respiratory failure. Based on past experiences regarding the effects of treatment with macrolides in patients with diffuse panbronchiolitis (DPB), long-term treatment with macrolides such as clarithromycin (CAM), erythromycin (EM) and azithromycin (AZM) has been empirically applied for the treatment of PCD in Japan (4-9). However, the effects of macrolide therapy in patients with PCD remain controversial. We herein report the cases of two PCD patients with different responses to macrolide treatment.

Case Reports

Case 1: A 17-year-old Japanese man had been diagnosed and treated for chronic sinusitis, exudative otitis media and bronchial asthma since his childhood. He had experienced repeated hemoptysis, and chest computed tomography (CT) had revealed right middle lobe bronchiectasis and collapse when he was 14 years old. He had been experiencing a productive cough and green sputum for one month prior to admission to our hospital. He was referred and admitted to our hospital via an internal medicine clinic that he initially visited because of hemoptysis, a low-grade fever (37.3°C) and exertional dyspnea [British Medical Research Council (MRC) dyspnea scale grade 3]. A physical examination upon admission showed blood pressure of 125/78 mmHg and a regular pulse of 125 beats/min. Lung auscultation re-
revealed expiratory wheezes in the right lung. The results of the laboratory data, arterial blood gas analysis and pulmonary function test on admission were as follows: white blood cell count, 15,000/μL; neutrophils, 77.9%; hemoglobin, 14.9 g/dL; cold agglutinin, ×4; pH, 7.398; PaCO₂, 43.6 Torr; PaO₂, 83.0 Torr; VC, 4.99 L; %VC, 99.0%; FEV₁, 3.72 L/sec; FEV₁, % 77.0%. A chest CT on admission showed diffuse fine granular shadows, thickening of the bronchial walls and patchy bilateral ground-glass opacities (A), in addition to the bronchiectasis of the collapsed right middle lobe (B). C: The chest CT findings of Case 1 two months after the first admission, showing improvement of these findings compared to those at the first admission. D: The CT findings of Case 1 sixteen months after the first admission indicating exacerbation of multiple fine granular opacities, even after long-term macrolide treatment with clarithromycin (CAM), erythromycin (EM) and azithromycin (AZM). E: The chest CT findings of Case 2 on admission showed diffuse fine granular shadows and thickening of the bronchial walls. F: The CT findings of Case 2 seven months after the first admission were almost completely improved by the treatment with CAM (200 mg/day).

The patient was diagnosed to have pneumonia in the right middle lobe and hemoptysis from the same lesion. He started to receive antimicrobials (meropenem) on the day of admission, and the chest CT findings 2 months after the first admission were improved (Fig. 1C). Pseudomonas aeruginosa was detected continuously in cultured sputum, and repetitive acute exacerbations of lower respiratory tract infections occurred in spite of long-term treatment with CAM (200 mg/day) (Fig. 2). Flexible bronchoscopy at 3 months after the first admission revealed a massive amount of yellowish bronchial secretions from the right middle lobe bronchus (Fig. 3A). An electron microscopic examination of biopsy specimens obtained from the bronchial mucosa revealed the combined defect of both IDA and ODA in the cilia (Fig. 3B). Based on these findings, the patient was diagnosed to have PCD. CAM was changed to EM (400 mg/day) beginning 3 months after the first admission, but the symptoms of the lower respiratory tract infections and hemoptysis were still uncontrolled.

Because the right middle lobe was considered to be the major source of infection and hemoptysis, surgical resection of the right middle lobe was performed 4 months after the first admission. After switching macrolides from CAM to
EM and the right middle lobe resection, the frequency of acute exacerbations of lower respiratory tract infections was decreased, although diffuse fine granular shadows and bronchial wall thickening on chest CT at 6 months after the first admission were exacerbated. EM was changed to AZM (2 g/2 weeks) beginning 8 months after the first admission, and no acute exacerbations were observed after the initiation of AZM. However, the findings of chest CT scans were worsened at 12 months and 16 months after the first admission (Fig. 1D), and a deterioration of the FEV1.0 was observed (Fig. 2). He also had a productive cough continuously after the initiation of the treatment.

Case 2: A 70-year-old Japanese man with a medical history of chronic sinusitis was admitted to our hospital after developing a persistent cough and yellow sputum. His chest CT showed diffuse fine granular shadows and thickened bronchial walls (Fig. 1E). Sputum microbiology revealed *Haemophilus influenzae* and *Moraxella catarrhalis*. The bronchoalveolar lavage fluid obtained from the right B3 contained an increased total cell count (13.7×10⁴/mL) with a high fraction of neutrophils (86.7%), a low fraction of lymphocytes (3.53%) and a low CD4/8 ratio (0.3). The deficiency of IDA in the cilia was revealed by the electron microscopic examination of the bronchial mucosal biopsy specimens (Fig. 3C), suggesting a diagnosis of PCD. Long-term treatment with CAM (200 mg/day) was started after the diagnosis and was maintained for 11 months. This treatment improved his symptoms of productive cough and purulent sputum. No acute exacerbations were observed after the initiation of CAM. The chest CT findings were also gradually improved at one month (showing slightly fine granular shadows) and 7 months (Fig. 1F, almost completely improved) after the initiation.

**Discussion**

We herein report two cases of PCD treated with long-term macrolides that showed different treatment responses. Case 1 had a combined defect of both IDA and ODA in the cilia and also had *Pseudomonas aeruginosa* infection. The patient showed a poor response to three different types of macrolides on both radiological findings and pulmonary function tests, although the frequency of acute exacerbations of lower respiratory tract infections was improved with AZM. On the other hand, Case 2 had only an IDA defect in the cilia, and demonstrated a good response to CAM.

PCD is a genetic disease associated with abnormal ciliary structure and function. The ciliary beat is an important primary innate defense mechanism and the dysfunction impairs the mucociliary clearance which protects the lungs from pathogens, pollutants and allergens. Repeated lower respiratory tract infections result in the progressive destruction of the lung that can lead to severe and fatal pulmonary dysfunction (10, 11). Thus, the severity of PCD, the degree of ciliary dysfunction and the specific ultrastructural abnormalities of the cilia are closely associated with each other (2, 3).
Chilvers et al. reported that the mean CBF was 12.8/second in normal subjects, whereas the mean CBF was 8.1, 2.3 and 0.8/second in patients with IDA, ODA, and dual IDA and ODA defect of the cilia, respectively (3). The ideal agents to...
treat patients with PCD should overcome the ciliary dysfunction (10). However, there are currently no effective therapeutic strategies that correct this inborn error, and macrolides do not seem to have an effect on the CBF (12). Beta2-adrenoreceptor agonists have been shown to enhance CBF in vitro (13, 14), though there is little data indicating that such agents improve the function of dyskinetic cilia. We also used this agent in Case 1, resulting in no obvious clinical effects. L-arginine is thought to have a potential role of enhancing CBF via increasing the airway nitric oxide levels, but the infusion of L-arginine to patients with PCD does not improve their pulmonary function and does not increase nasal nitric oxide levels high enough to reach the same levels of healthy individuals (15).

Accordingly, it is difficult to cure the patients with PCD completely, and the management of lower respiratory tract infections in these patients is very important to delay or stop the disease progression (10, 11). The respiratory management of PCD is basically based on that for cystic fibrosis (CF) in European and North American countries, and is based on that of DPB in Japan. Many therapeutic agents have been tried for PCD, however, there have been no randomized controlled trials, and there are currently no standardized therapeutic strategies (10, 11). From the clinical experiences of the efficacy of macrolides in patients with DPB, long-term treatment with macrolides has been used for patients with PCD in Japan (4-9). The nine reported cases of PCD, including the present two cases, with ultrastructural abnormalities in the cilia treated by long-term macrolide administration are summarized in Table 2. Four patients with a defect of only IDA in the cilia were all clinically and radiologically improved by long-term treatment with macrolides. On the other hand, two of five patients with a combined defect of both IDA and ODA in the cilia did not respond to the treatment with macrolides in clinical respiratory symptoms, and also three of five patients did not respond based on the radiological findings. From these findings, we speculate that the different severity of ultrastructural abnormalities of the cilia may be one of the predictive factors of response to macrolide treatment in patients with PCD. While PCD is a rare disease and it is not easy to perform a protective study, further accumulation of evidence is expected to confirm our speculation. Persistent lower respiratory tract Pseudomonas aeruginosa infection is also well known as one of the poor prognosis factors of lung diseases including DPB and PCD (2, 16, 17). As listed in Table 2, Pseudomonas aeruginosa was detected from sputum culture in all three cases without a response to long-term treatment with macrolides radiologically, supporting the results of these previous reports (2, 16, 17). Considering that Pseudomonas aeruginosa was detected in three of five cases with a combined defect of both IDA and ODA in the cilia, and one of four cases with a defect of IDA in the cilia (Table 2), the different severity of ultrastructural abnormalities of the cilia may also be closely associated with Pseudomonas aeruginosa infection. Other than these factors, disease severity and genetic heterogeneity have been considered to be predictive factors of the response to macrolides, and they also seem to be closely related to ultrastructural abnormalities of the cilia (1, 8, 18, 19).

Long-term treatment with macrolides has been shown to improve the prognosis of DPB (20). The 14- and 15-member-ring macrolides improved the clinical outcomes of patients with DPB, and there has recently been much attention focused on the use of macrolides as a potential therapy for other inflammatory airway disorders, such as bronchial asthma, bronchiectasis, chronic obstructive pulmonary disease, chronic rhinosinusitis, cystic fibrosis and obliterative bronchiolitis (21). As antimicrobial agents, macrolide antibiotics including CAM are widely used as first-line agents to treat acute bacterial infections such as community-acquired pneumonia (22). In addition to their antimicrobial activities, macrolides inhibit airway mucus secretion, decrease the infiltration and prolongation of the activation of inflammatory cells such as lymphocytes, macrophages and neutrophils in the lungs, and decrease the production of cytokines such as interleukin (IL) -1, -2, -6 and -8, and tumor necrosis factor-α from the lungs (23-30). The mechanisms of action of the macrolides are thought to be due to the immunomodulatory effects of the agents, rather than their direct antimicrobial activities (21). Based on these reports, we speculated that macrolides could improve the airway inflammation in patients with PCD through their immunomodulatory activities. The differences in the effects of each macrolide on the immune system are still unclear; AZM seemed to be more effective than the other macrolides in Case 1 having a combined defect of both IDA and ODA with persistent lower respiratory tract infection of Pseudomonas aeruginosa, reducing the frequency of acute exacerbations. It suggests that to stop the disease progression of PCD completely is difficult, but using AZM in an earlier stage of PCD may be better to delay the disease progression in severe cases.

In conclusion, this report describes two cases of PCD with different responses to macrolide treatment. Though the reason for the differing responses to macrolides is still unclear, differences in ultrastructural abnormalities of the cilia might be one of the predictive factors of the response to macrolides in PCD. While PCD is a rare disease, further accumulation of the evidence regarding the relationship between the response to macrolides and ultrastructural ciliary abnormalities is expected to confirm our speculation. Macrolides may have the potential to ameliorate the natural course of PCD with mild ciliary dysfunction via the modification of the activities of the immune system, although the complete suppression of disease progression is difficult to be accomplished, especially in severe cases. AZM seems to be a better choice than other macrolides for patients with PCD in order to reduce the frequency of acute exacerbations and delay the disease progression, according to the clinical course of Case 1.

The authors state that they have no Conflict of Interest (COI).
References


© 2012 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imindex.html

1098